Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) gapped down before the market opened on Tuesday . The stock had previously closed at $19.88, but opened at $19.09. Pulse Biosciences shares last traded at $19.10, with a volume of 53 shares trading hands.
Several analysts recently commented on the stock. Zacks Investment Research raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, April 28th. Maxim Group assumed coverage on Pulse Biosciences in a research report on Wednesday, March 17th. They set a “buy” rating and a $40.00 price target on the stock. Finally, HC Wainwright increased their price target on shares of Pulse Biosciences from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, February 4th.
The company has a market cap of $493.91 million, a price-to-earnings ratio of -8.76 and a beta of 1.88. The business has a 50-day simple moving average of $22.53 and a two-hundred day simple moving average of $23.24.
Several institutional investors have recently modified their holdings of the stock. Bender Robert & Associates bought a new stake in shares of Pulse Biosciences in the first quarter worth $209,000. Westside Investment Management Inc. lifted its holdings in Pulse Biosciences by 2.9% in the first quarter. Westside Investment Management Inc. now owns 32,368 shares of the company’s stock valued at $766,000 after buying an additional 906 shares during the period. JPMorgan Chase & Co. lifted its holdings in Pulse Biosciences by 523.4% in the fourth quarter. JPMorgan Chase & Co. now owns 31,836 shares of the company’s stock valued at $760,000 after buying an additional 26,729 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Pulse Biosciences by 7.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,608 shares of the company’s stock valued at $802,000 after buying an additional 2,406 shares during the period. Finally, Wolverine Trading LLC acquired a new position in Pulse Biosciences in the fourth quarter valued at $276,000. 11.42% of the stock is currently owned by institutional investors.
About Pulse Biosciences (NASDAQ:PLSE)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.